榄香烯联合三苯氧胺对乳腺癌MCF-7细胞株的抑制效应

目的观察榄香烯和三苯氧胺对乳腺癌细胞的抑制效应,尤其是两者联合应用有无协同增效作用。方法将MCF-7细胞培养于RPMI1640培养基中,置入37℃,100%湿度,5%(体积分数)的CO2培养箱内。接种细胞并加入实验药物,用CCK-8法检测三苯氧胺联合榄香烯对细胞的增殖抑制效应,用酶标仪在450nm测量每孔吸光度值,计算每组细胞抑制率。结果无毒剂量的榄香烯与治疗剂量的三苯氧胺联合应用,吸光度均值较单用三苯氧胺明显下降,并且相应的细胞抑制效应较单用组明显上升。结论无毒剂量的榄香烯能够使三苯氧胺对乳腺癌细胞的抑制效应显著增强,提示榄香烯与三苯氧胺联合应用具有协同作用。     

Induction of apoptosis and inhibition of proliferation of C6 glioma cells in vitro by tamoxifen

Objective To investigate the anti-tumor effect and mechanism of tamoxifen on rat C6 glioma cells. Methods C6 cells were cultured in Dulbecco＇s modified Eagle＇s medium （DMEM） with 3% fetal calf serum （FCS）, and treated with tamoxifen of different concentrations, i.e. group A （1.25 μmol/L）, group B （2.50 μmol/L）, group C （5. 00 μmol/L）, group D （10. 00 μmol/L）, group E （20. 00 μmol/L） and control group （0. 00 μmol/L）. Morphological changes, MTT assay and 5-bromo-2＇-deoxyuriding labeling ratio were assessed. Apoptosis was observed by flow cytometry. Results C6 cells treated with different doses of tamoxifen for 24, 48, and 72 hours became irregular in shape, while cells treated with vehicle grew normally. MTT assay showed that tamoxifen did not suppress C6 cell growth until 72 hours after treatment. Seventy-two hours after treatment, there were significant differences in cell viable rate between group A versus groups C, D and E; so did group B versus group D as well as group E （P〈 0.05 ）. BrdU incorporation assay indicated significant difference of BrdU labbled index （BrdU LI） among groups A, C, E and control group 48 hoers after treatment （P〈0.05）. And the BrdU LI decreased with the increased concentration of tamoxifen. Flow cytometry （FCM） showed significant difference between treated group and control group at 24, 48, and 72 hours after treatment （P〈0.05）. Conclusion Tamoxifen significantly suppresses the growth of C6 glioma cells in a time- and dose-dependent manner. The mechanism of tamoxifen suppressing C6 glioma cells may be inhibiting proliferation and inducing apoptosis. Therefore, tamoxifen can be a candidate as a chemotherapy agent for glioma.     

Research on pharmacokinetics of high-dose tamoxifen in non-small cell lung cancer patients

Objective To study the pharmacokinetics of tamoxifen at a high dosage, which will offer a theoretical support for an appropriate clinical use of the medicine in non-small cell lung cancer （NSCLC） patients. Methods Three qualified NSCLC patients are selected and given tamoxifen （TAM） 160 mg per Os. Blood samples were collected at different times and then analyzed by high-performance liguid chromatography. The PK-GRAPH program was used to obtain the parameters. Results The concentration-time courses of the TAM 160 mg were fitted to one-compartment model. The pharmacokinetic parameters were estimated as follows： Tmax （6. 35±1. 24）h, Cmax （217. 39±7. 71）ng/mL, AUC （12 127.39±636.16）ng · h/mL and T1/2ke（34. 13±2.97）h. Conclusion TAM 160mg one day per Os cannot reach the effective maintenance concentration in vivo required for reversing MDR in vitro. Loading-maintenance dose strategy is recommended to study the pharmacodynamies of tamoxifen at a high dosage in NSCLC patients.